中文摘要：

目的调查HIV-1感染人群抗病毒治疗后HIV-1辅助受体的利用情况。方法从安徽、河南两地选择109例接受抗病毒治疗的HIV-1感染者和45例未接受抗病毒治疗的HIV-1感染者作为研究对象，通过周围血单个核淋巴细胞（PBMCs）共培养方法，分离培养HIV-1临床毒株，利用酶联免疫吸附法检测培养上清HIV-1的P24含量，通过表达趋化因子CCR5和CXCR4的Ghost细胞系检测病毒辅助受体利用，对治疗人群中HIV-1辅助受体利用因素进行探讨，并与治疗因素进行分析讨论。结果从治疗人群中分离了45株病毒，其中22株病毒（48．89％）利用CCR5辅助受体，是R5嗜性毒株；21株病毒（46．67％）利用CXC4／CCR5辅助受体，为双嗜性（X4／R5）毒株；有2株（4．44％）仅利用CXCR4辅助受体，为x4嗜毒株。从未治疗人群中分离了109株病毒，其中96株（88．07％）利用CCR5辅助受体（R5嗜性毒株）；13株（11．93％）为X4／R5双嗜性毒株。HIV-1CXC4／CCR5辅助受体利用率在两组中的差异有统计学意义（χ^2=27．30，P〈0．05）。治疗方案一（齐多夫定、去羟肌苷、奈韦拉平三联用药）治疗后HIV-1CXCA／CCR5的利用率为59．09％（13／22），治疗方案二（司他夫定、去羟肌苷、奈韦拉平三联用药）治疗后HIV-1CXCA／CCR5的利用率为43．48％（10／23），二者对HIV-1辅助受体利用的影响差异没有统计学意义（χ^2=1．10，P=0．30）。结论在HIV-1感染者中，接受抗病毒治疗人群中HIV-1CXCR4／CCR5利用率高于未治疗人群。

英文摘要：

Objective To investigate HIV-1 co-receptor usage in patients experienced anti-retroviral therapy （ART） in Anhui and Henan province of China. Methods A total of 45 HIV-1 infected individuals who have experienced ART and I09 un-experienced ART patients from Anhui and Henan province,which were called as treatment group and treatment-negative group, were selected as study subjects. HIV-1 strains were isolated from peripheral blood mononuclear cells of whole blood from patients. HIV-1 p24 in the culture supernatant was measured using a commercial enzyme-linked immunosorbent assay（ELISA） kit. HIV-I co- receptor usage was identified using Ghost cell lines expressing CD4 and the chemokine receptor CCR5 or CXCR4. Results Among 45 HIV strains from the treatment group,22 （48.9%） strains used CCR5 as a co- receptor （R5 tropic strain）,21 （46. 7% ） strains used CXCR4/CCR5 as a co-receptor （X4/R5 duel tropic strain） ,and 2（4. 4% ） used only CXCR4 as a co-receptor（X4 tropic strain）. In 109 strains from treatment- negative group,96 （88. 1% ） strains used CCR5 as a co-receptor（R5 tropic strain）,13（ 11.9% ） strains used CCRS/CXCR4 as a co-receptor use （X4/R5 strain ）. A significant difference was found between two groups in X4 co-receptor usages（χ^2= 27.30, P 〈 0. 05 ）. Furlhermore, after treated with AZT ＋ DDI ＋ NVP, the HIV-l CXC4/CCR5 utilization was 59. 09% （ 13/22）, meanwhile after treated with D4T ＋ DDI ＋ NVP, the HIV-1 CXCA/CCR5 utilization was 43.48% （10/23）,which the difference was not statistical significant （ χ^2 = 1. 10, P = O. 30）. Conclusion HIV-1 CXCRd/CCR5 co-receptor utilization was higher in ART patients than treatment-negative patients.